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Abstract 
Alzheimer’s disease (AD) is a genetically complex disorder, and rare variants were recently 
identified in the TREM2 gene that as much as triple an individual’s risk of developing AD. 
TREM2 is a transmembrane receptor expressed in cells of the myeloid lineage, and the 
association with AD confirmed the involvement of immune and inflammatory pathways in the 
etiology of the disease, as opposed to a reaction. TREM2 variants associated with AD induce 
partial loss of function of TREM2 protein and alter the behavior of microglial cells, including their 
response to amyloid plaques. TREM2 variants have also been found to cause polycystic 
lipomembranous osteodysplasia with sclerosing leukoencephalopathy and FTD. Although the 
low frequency of TREM2 variants makes it is difficult to establish robust genotype-phenotype 
correlations, such studies are essential to enable a more comprehensive understanding of the 
role of TREM2 in different neurological diseases, with the ultimate goal of developing novel 
therapeutic approaches. 
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Introduction 
Alzheimer’s disease (AD) has a complex genetic architecture with rare, highly penetrant, 
mutations in the amyloid precursor protein (APP), presenilin-1 (PSEN1) and presenilin-2 
(PSEN2) genes, ~30 common low risk genetic loci 1 and the Ɛ4 allele of APOE which has an 
intermediate frequency in the population and imparts intermediate risk for disease. Identifying 
additional genetic variants with frequencies and effects similar and lower to the ones conferred 
by APOE has been exceedingly difficult given the need for extremely large cohorts of cases and 
controls. However, these variants have the potential to add significantly to our understanding of 
the biology of the disease process. 
Whole genome analyses led to the identification of a rare variant in TREM2 - a gene that 
encodes a receptor expressed in myeloid cells that mediates inflammatory responses (panel) -   
imparting a risk for AD similar to that conferred by one copy of the APOE Ɛ4 allele (increasing 
risk for AD by approximately 3-fold)2,3. The importance of TREM2 in brain function is also 
highlighted by the fact that rare, biallelic mutations in the gene cause polycystic 
lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL, also known as 
Nasu-Hakola disease)4 and, in some cases, frontotemporal dementia (FTD)5. Understanding the 
biological functions of TREM2 in the brain is essential for the identification of potential 
therapeutic targets and, possibly, new candidate genes 6. 
In this Review, we discuss the reported genetic associations of TREM2 with neurodegenerative 
diseases, as well as the effects of these variants on pathology, clinical presentation, and 
underlying biology.  We cover AD, PLOSL, and FTD, with an emphasis on AD, as it is the most 
common neurological disease associated with TREM2, and many advances in understanding 
TREM2’s role in the brain have been made in AD. Specifically, we assess the evidence for the 
association of identified TREM2 variants with AD risk, summarise genotype-phenotype 
correlations, evaluate the potential use of soluble TREM2 (sTREM2) as a CSF biomarker, and 
summarise the biological effects of loss of TREM2 function. We underscore the importance of 
integrating multi-disciplinary findings related to TREM2 and introduce an on-line resource at 
Alzforum that aggregates existing and emerging results pertaining to neurological disease. 
TREM2 in Alzheimer’s disease 
TREM2 variants and AD risk 
So far, a total of 63 coding genetic variants have been identified in TREM2 with varying 
frequencies in the general population. One of these, a rare variant (p.R47H, rs75932628) has 
been found to increase the risk of developing AD by 2 to 3-fold in several European and North-
American populations 2,3,7–10. A significant association with AD between a proxy of rs75932628 
and AD was also found in black patients 11. However, in Chinese cohorts, p.R47H was not 
detected in patients with late-onset AD or healthy controls 12–15 and no association between 
TREM2 variants and AD risk was found in Japanese 16, Korean 17 or Iranian 18 cohorts, which 
suggests that effect of TREM2 is population-specific. 
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Studies in family based datasets found a weak but significant association between p.R47H and 
AD risk 19,20. In a study 21 of 130 families with late-onset AD, TREM2 p.R47H was found in 4 
families (3%, a value 10 times higher than that in the general population) and in a large family 
with late-onset AD, 12 patients (75%) with AD were found to carry the p.R47H allele, with 
vertical transmission of the disease observed only through p.R47H carriers. 
Other TREM2 variants have also been tested for association with AD risk (appendix, for an up 
to date interactive representation of mutations in TREM2 see 
https://www.alzforum.org/mutations) with only p.R62H showing genome-wide association levels 
of significance 7 and shown to be independent of the p.R47H association 8. Two studies of 
Chinese cohorts revealed two novel variants p.A130V14 and p.A192T22 exclusively in patients 
with late-onset AD. The variants p.H157Y and p.S183C were more frequent in Chinese patients 
with AD, with p.H157Y being significantly associated with increased risk for late-onset AD 22, 
contrary to what had been found in Caucasian cohorts. Subsequent functional studies have 
added evidence to the involvement of this variant in AD by identifying amino acid 157 as the site 
of protein shedding with p.H157Y accelerating the cleavage process and resulting in less full-
length protein on microglia 23,24. In the African American population only the variants p.W191X 
and p.L211P showed suggestive associations with risk for late-onset AD 25. The identification of 
different variants associated with risk for AD in the Chinese and African Americans  shows the 
importance of studying the association of rare variants with disease in different populations, as 
mutations occur at different rates  across different populations, leading to differences in the 
spectrum of segregating polymorphisms. 
In addition to TREM2 variants, other changes located in the TREM gene cluster have been 
reported to be associated with AD risk or to regulate TREM genes expression. An intergenic 
SNP located 5.5Kb downstream from TREML2 and 24 Kb upstream from TREM2 (rs9381040) 
was shown to act as a protective allele for AD 26. Similarly, a TREML2 missense variant 
(p.S144G, rs3747742) was also found to reduce the risk for AD 27. The association of these two 
variants appears to be independent of p.R47H 27. An association with reduced risk of AD was 
reported for rs9357347, located within a DNase hypersensitive site between TREM2 and 
TREML2 28. This variant is in linkage disequilibrium with rs9381040 and the authors considered 
rs9357347 as a regulatory and functional variant, since it was also associated with increased 
TREML1 and TREM2 mRNA levels 28. 
Having variants that are robustly associated with AD and have appreciable effect sizes opens 
the possibility to genetic risk prediction, particularly when vertical transmission has been 
observed. However, the effect sizes of these variants are too low to allow risk prediction. 
Although the p.R47H variant has an odds ratio that is comparable to one copy of the Ɛ4 allele in 
APOE—on its own, is not helpful in clinical risk prediction. Additionally, given the rarity of these 
variants it is unlikely they will have an impact on risk prediction at the population level, but it may 
be useful to include TREM2 variants in polygenic risk predictions for AD in a small subset of 
cases. None of these variants are disease-causing and, with the exception of p.R47H and 
p.R62H, all other associations still need to be independently replicated by large cohort studies. 
Genotype-phenotype correlation 
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Several studies have tried to correlate the presence of TREM2 variants with AD-related 
phenotypes, but so far too few carriers have been studied to reach definite conclusions. In 
general, patients with AD carrying TREM2 variants show similar clinical, neuroimaging and 
neuropathology features to those seen in sporadic cases 2,21,29. 
In a clinic-based dataset of 563 patients with AD, 12 were carriers of p.R47H and have been 
reported to have lower age at onset when compared to 551 non-carrier patients with AD (mean: 
55.2 years vs. 61.7 years), respectively 29. In fact, most of these 12 carriers of p.R47H had an 
age at onset below 65 years, with 4 below 50 years and no other known genetic risk variants. 
These results are consistent with those reported for the Icelandic and Dutch populations in 
whom the presence of the risk allele led to an age at onset of AD that was lower by 3.18 and 
3.65 years than in non-carriers of the variant, respectively 21. However, in five families with late-
onset AD, when comparing the age of onset of p.R47H carriers (n=16) with non-carriers (n=18), 
the mean did not differ between groups. In these same families, disease duration was 
significantly shorter in carriers than in non-carriers 21.  
In a cohort of asymptomatic middle-aged adults, p.R47H carriers had a higher probability of 
having a parental history of AD, with a younger maternal age of AD onset; while no differences 
were observed in cognitive function or rate of decline 37. However, in the Icelandic population, 
non-demented carriers with ages between 80 and 100 years exhibited poorer cognitive function 
than non-carriers of p.R47H 3. 
The presence of TREM2 p.R47H showed no association with psychosis, amyloid deposition in 
the brain, or family history 9,30. Higher density of Aβ plaques and neurofibrillary tangles 31 and 
more frequent α-synucleinopathy 21 have also been observed in patients with TREM2 p.R47H. 
In a Spanish cohort, AD carriers of p.R47H showed apraxia, psychiatric symptoms such as 
personality changes, anxiety, paranoia or fears and parkinsonian signs more frequently than AD 
non-carriers, particularly during the first 2 years after disease onset 32. Higher frontobasal gray 
matter cortical loss was also reported in p.R47H carriers in this cohort, which could be 
speculatively related to the FTD phenotype associated with some TREM2 variants 32. 
Patients with TREM2 p.R47H were also found to have significantly higher levels of total tau and 
phosphorylated tau (p-tau) in CSF, whereas Aβ42 levels were comparable to expected 
concentrations for the stage of disease 33,34. When compared to non-carrier controls, AD 
patients carriers of p.R47H were also found to have higher CSF sTREM2 levels 35. In the same 
study p.R62H showed no difference to controls but other TREM2 variants were found to be 
associated with lower levels of CSF sTREM2 with the lowest levels identified in carriers of 
heterozygous PLOSL-causing variants 35. 
By studying TREM2 rs9394721 (a proxy for p.R47H) in the Alzheimer's Disease Neuroimaging 
Initiative cohort, it was found that variant carriers annually lost 1.4% to 3.3% more of their brain 
tissue than non-carriers, in a pattern that mirrored the profile of AD in the brain.42 The risk allele 
was also found to be significantly associated with smaller hippocampal volumes, elevated levels 
of the CSF p-tau, and poorer cognitive performance compared to non-carriers 36.   
Given that leukoaraiosis is commonly seen in patients with PLOSL it is interesting to note that 
no significant changes in white matter have been described for AD patients with TREM2 
variants 32. No differences between carriers and non-carriers of p.R47H have been seen when 
using the Scheltens scale (semi-quantitative visual rating scale used to measure the presence 
of hyperintense white matter lesions in MRI) or when looking specifically for clusters of white 
5 
matter hyperintensities 32. Similarly, neuropathology assessment of brain tissue from AD carriers 
of TREM2 variants showed white matter abnormalities within what would be expected for typical 
AD 2. 
Variants located in the TREM locus have also been associated with AD-related phenotypes. For 
example, TREML2 variants p.S144G and rs6916710, and the intergenic variant rs6922617 were 
found to be associated with CSF p-tau levels 27,34. The TREM1 intronic variant rs6910730 was 
found to increase the burden of neuritic and diffuse plaques, as well as of Aβ density, while 
rs7759295 was associated with increased tau tangle density and increased burden of 
neurofibrillary tangles 38. Both variants were associated with an increased rate of cognitive 
decline 38. It is plausible that many, or even all, of the variants reported with correlations with 
AD-associated phenotypes, may be in linkage disequilibrium with the functional variant and 
consequently may reflect indirect associations. 
Larger cohorts and replication studies are required to enable robust genotype-phenotype 
correlations. The available data suggest that AD patients carriers of TREM2 variants are similar 
to typical patients with AD with an initial amnesic syndrome, but perhaps presenting earlier age 
at onset and faster loss of brain tissue (particularly in frontobasal cortical regions) which is 
possibly associated with a more rapid progression into multidomain dementia. Although these 
findings do not have, as of yet, a direct impact in clinical practice, identifying carriers of TREM2 
variants may be important in patient stratification for clinical trials and future individualised 
therapeutic approaches. 
sTREM2 as a CSF biomarker 
sTREM2 is released to the extracellular space after proteolytic cleavage and can be detected in 
human plasma and CSF in both healthy and AD subjects 39. Even though the physiological and 
disease-associated functions of sTREM2 are unknown, this form of the protein has been 
suggested to have protective effects on microglial cell viability 40. Additionally, AD-risk 
associated variants were shown to reduce the overall capacity of sTREM2 to enhance cell 
viability and to trigger inflammatory responses in microglia 40. Although the physiological 
relevance of these results is not clear, it is interesting to consider that sTREM2 may act 
independently, and possibly with opposing roles, to the full-length protein in the regulation of 
inflammatory responses. 
Although the initial studies 39,41 examining the differences in CSF sTREM2 levels between 
patients with AD and healthy individuals did not show any differences 39 or showed reduced 
levels in patients with AD compared to healthy controls 41, subsequent studies have consistently 
found higher levels of CSF sTREM2 in patients with AD compared to healthy controls 35,42,43. 
These apparently contradictory findings may stem from differences in the assays used or from 
the focus on different stages of disease progression. CSF sTREM2 levels change during 
disease progression with a peak at the clinical MCI stage of AD 43. In a cross-sectional study 44 
of individuals enrolled in the Dominantly Inherited Alzheimer’s Network, carriers of PSEN1, 
PSEN2, or APP AD-causative mutations were found to have elevated levels of CSF sTREM2 
compared with non-carriers; this difference became apparent five years before the expected 
onset of symptoms in the mutation carriers and remained significant until five years after 
expected onset. In this cohort, elevations in CSF sTREM2 followed brain amyloidosis and 
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elevations of CSF tau, and were concurrent with the presence of cerebral hypometabolism and 
hippocampal atrophy 44. Other studies revealed that levels of CSF sTREM2 positively correlate 
with levels of CSF p-tau and total-tau, 35,39,42,43 but not with CSF Aβ42 35,42. These findings 
suggest a dynamic response of sTREM2 during the disease process, that may reflect an 
association between microglial activity and the first signs of degeneration 43,44,45. 
Despite the significant association between CSF sTREM2 levels and AD at the group level, CSF 
sTREM2 only achieves a discriminative power of around 60%, which is lower than the 80-90% 
required to be useful in clinical diagnostic procedures 46. Nonetheless, if CSF sTREM2 levels 
are reproducibly associated with the onset of cognitive decline,CSF sTREM2 could provide an 
independent measure of disease stage, marking the transition from preclinical AD to dementia, 
and could be useful for clinical trials. 
TREM2 mechanisms in AD 
The identification of TREM2 variants as risk modifiers for AD stimulated research into the 
pathobiological mechanisms mediated by this microglial receptor. Neuropathology in patients 
with AD and animal models, coupled with in vitro studies of the biochemical and cell biological 
effects of TREM2 variants, indicate that AD-associated risk variants cause partial loss of 
function of the protein. 
As the resident immune cells of the brain, microglia continuously survey the brain to respond to 
foreign invaders, while providing trophic support for neurons and phagocytosing cellular debris 
47. Microglia surround amyloid plaques in the brains of patients with AD and of animal models of 
amyloidosis, and it has been suggested that these microglia form a physical barrier that 
encapsulates neurotoxic amyloid-β48,49. Fewer plaque-associated microglia were seen in 
patients heterozygous for the p.R47H and p.R62H variants compared with the brains of patients 
without TREM2 risk variants 50, and more severe plaque-associated neuritic dystrophy 
accompanied reduced microglial coverage in the brains of p.R47H patients with AD 48. The 
effect of the p.R47H variant on microglial clustering around plaques was recapitulated in a 
mouse model of amyloidosis in which the mouse Trem2 gene was replaced with either the wild-
type or p.R47H variant of human TREM2 51. 
The role of TREM2 in the context of amyloid pathology has been further studied by manipulating 
TREM2 gene dosage in mouse models of amyloidosis. Fewer microglia surrounded plaques in 
animals lacking or haploinsufficient for TREM2 49,52, similar to what is seen in the brains of 
patients with AD carrying the p.R47H or p.R62H alleles, suggesting that the AD-associated 
variants are partial loss of function mutations. Plaque-associated neuritic dystrophy was also 
more severe 48,49 and neuron loss was exaggerated in mice deficient for TREM2, in a gene-dose 
dependent manner 53. The effects of TREM2 dosage on amyloid burden are more complex. 
Genetic ablation of TREM2 resulted in less severe plaque pathology at early stages of plaque 
deposition but in more severe plaque pathology at later stages 49,52–54. Elevating levels of 
TREM2 through the introduction of a human TREM2 transgene reduced pathology in amyloid-
bearing mice 55. Specifically, amyloid burden was reduced and plaques were remodeled from a 
fibrillary type to a more compact and possibly less toxic form. Furthermore, microglial 
phagocytic activity was increased, the number of plaque-associated microglia was reduced, and 
cognitive function was rescued 55. 
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The biochemical and cell biological effects of AD-associated variants in TREM2 have been 
studied extensively in vitro. AD-associated TREM2 variants do not significantly affect the 
folding, trafficking, or expression of TREM2 41,53,56,57, but do impair ligand binding and uptake 
7,41,53,57–62
. Although the endogenous ligands of TREM2 are not known, molecules that act as 
TREM2 ligands under experimental conditions—and that display reduced binding to AD-
associated TREM2 variants—include anionic or zwitterionic lipids that may be exposed during 
neuronal and glial degeneration and associate with fibrillar amyloid-β 53, ApoE 60,61, and 
oligomeric amyloid-β 58. 
Two theories have emerged to explain how the loss of TREM2 function might impair the 
microglial response to amyloid pathology and exacerbate disease: 1) TREM2 signaling is 
necessary to reprogram cells from a homeostatic to a neuroprotective disease-associated 
phenotype 50,63,64, and 2) tonic TREM2 signaling is necessary to support microglial metabolism, 
and loss of TREM2 function severely impairs microglial fitness and capacity to respond to 
stressors 65.  
In support of the first theory, plaque-associated microglia adopt a gene expression profile 
distinct from that of microglia in healthy brain (homeostatic microglia), characterized by 
increased expression of genes associated with lipid metabolism and phagocytosis 50,63. TREM2 
is necessary for microglia to undergo this phenotypic switch 50,63. It has been suggested that the 
plaque-associated microglial phenotype may be neuroprotective, promoting phagocytosis of 
amyloid plaques and/or degenerating neurites 63, and that microglia locked into a homeostatic 
state could be detrimental 64. In support of the second theory, TREM2-deficient microglia have 
abundant autophagosomes, believed to indicate metabolic stress, and decreased expression of 
genes involved in biosynthesis and energy metabolism - a state very different from homeostatic 
microglia 65. Notably, augmenting ATP levels with dietary cyclocreatine ameliorated the effects 
of TREM2 deficiency on the microglial response to plaques in amyloid-bearing mice, providing 
support for the hypothesis that metabolic deficits underlie the effects of TREM2 loss of function 
on at least some aspects of AD-related pathology 65. 
The mechanisms through which TREM2 influences AD may be multiple and complex. It is 
possible that TREM2-mediated microglial activity might be both protective and damaging, 
depending on the stage of disease progression and the specific microglial activity (e.g., 
phagocytosis of potentially damaging material versus generation of potentially damaging 
cytokines). To date, only very few studies have examined the effects of TREM2 deficiency in the 
context of tauopathy and no consistent picture has yet emerged 66–68. The availability of new 
animal models expressing disease-associated TREM2 variants and of induced pluripotent stem 
cells derived from patients with AD carrying TREM2 mutations should accelerate research 
aimed at better defining the role of TREM2 in the development and progression of AD. 
TREM2 mutations cause PLOSL 
PLOSL, also known as Nasu-Hakola disease, is a very rare, autosomal recessive disease 
characterized by spontaneous bone fractures and early-onset dementia 4. In Finland, it has an 
estimated prevalence of 1 to 2 per million people 69. It has been diagnosed in over 100 cases in 
the Japanese population 69 and appears to be less common in other all other worldwide 
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populations 70 with the first report from India just recently published 71. It is a genetically 
heterogeneous syndrome caused by biallelic (homozygous or compound heterozygous) 
mutations in two genes—TREM2 or TYROBP 4. The natural course of the disease can be 
divided into four stages: latent, osseous, early neurological, and late neurological 72 (appendix). 
Several other mutations in the gene have been reported to cause PLOSL (appendix). 
In the first report linking TREM2 mutations with PLOSL, of the 39 patients studied, TYROBP 
mutations were identified in 31 (79%) patients and TREM2 mutations in the remaining 8 (21%) 
patients 4. Note that 25 of these patients carried the same 5.3kb deletion encompassing exons 
1-4 of TYROBP 4 suggesting that this is a founder mutation in the Finnish population and should 
be tested for specifically in Finnish patients. The genetic study of a Finnish family harbouring 
this TYROBP deletion revealed the co-occurrence of other variants in neurologically-associated 
genes, including a C9ORF72 expansion which was thought to be an incidental finding with no 
clinical expression (most likely due to the higher frequency of both genetic changes in this 
population), and a novel mutation in EPM2A, a gene implicated in progressive myoclonic 
epilepsy type 2 (Lafora disease), that was suggested to be responsible for the severe epilepsy 
seen in the corresponding case of this Finnish family 73. AD pathology has also been studied in 
PLOSL patients. Amyloid-PET revealed extensive Aβ deposition in the grey matter of the inferior 
frontal and occipital lobes of an Italian patient carrying a TREM2 homozygous p.Q33X mutation 
74. Neuropsychological and functional nuclear imaging (99mTc-ECD SPECT) tests in 
heterozygotes in a family carrying this same mutation showed deficits of visuospatial memory 
associated with hypoperfusion in the basal ganglia implying an overlap of pathogenic 
mechanisms between AD and PLOSL 75. However, immunohistochemistry analyses of five 
brains of patients with PLOSL revealed no amyloid plaques or amyloid angiopathy, and only a 
small number of tau-tangle bearing neurons, mostly in the hippocampus, suggesting that 
TREM2 loss of function does not accelerate AD pathology 76. Additionally, analyses of TYROBP 
genetic variability have also not shown associations with cognitive impairment in a Finnish 
cohort 77 or as the cause of dementia in Turkish patients 78.  
The implication of TYROBP and TREM2 mutations in PLOSL led to the identification of the 
signaling pathway 4 responsible for this disease. The finding that these genes are both 
expressed in microglia and osteoclasts partially explained the peculiar tissue distribution of 
symptoms. However, it is still unclear why some patients (sometimes harbouring the same 
mutation) develop bone cysts and pathological fractures associated with dementia, while others 
present with FTD (for an overview of phenotype by mutations, see Supplementary Figure 3). It 
is tempting to speculate that genetic modifiers play a role in these disparate phenotypes, 
however achieving large enough sample sizes to identify them for variants that have such a low 
frequency in the population will be challenging. Despite this, it would be important to understand 
which factors influence these differences in presentation as these may be protective and 
potential targets for preventive or symptom management therapies. 
TREM2 in frontotemporal dementia 
Biallelic TREM2 mutations have also been described in 10 families diagnosed with FTD without 
the PLOSL bone phenotypes 79–86 (appendix). Some of these variants were previously known to 
cause PLOSL, while others are newly identified causes of disease. There seems to be no 
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correlation between the type of mutation and the associated phenotype since nonsense, splice 
site, and missense mutations have now been shown to cause both diseases 81. For a discussion 
of the mechanisms involved in PLOSL and FTD caused by TREM2 mutations, see appendix. 
Dementia in the form of an early-onset personality change, resembling behavioural variant FTD, 
seems to be the most common feature of all the reported FTD cases with biallelic TREM2 
mutations. A family history of consanguinity together with atypical features, such as seizures 
and corpus callosum atrophy, in a patient presenting with a behavioural FTD phenotype, should 
prompt the diagnostician to look for biallelic TREM2 mutations. This genetic cause should also 
be included in the differential diagnosis of young-onset dementia patients with seizures 81. 
Novel heterozygous TREM2 variants in patients with suggestive clinical presentations should be 
critically assessed and not assumed to be disease causative. Only in the presence of 
informative co-segregation of the variant with disease in a family, or unbiased functional effects 
in cell biology assays resulting in meaningful phenotypes should such variants be considered as 
disease causing. Association of TREM2 heterozygous variants with risk for FTD is currently 
controversial with several contradictory results reported. The p.T96K variant was associated 
with FTD subtypes 87 and a substantial burden of TREM2 heterozygous variants was reported in 
patients with FTD when compared to healthy controls 10,88. The p.R47H variant was found to be 
associated with FTD risk in a North American cohort 89 but not in European cohorts 9,29,90. 
Furthermore, a large meta-analysis of patients carrying p.R47H did not show a significant 
association with risk for FTD 33. These findings point to a possible association of TREM2 with 
the risk of FTD at the gene level, but without any reliable associations at the variant level. These 
inconclusive results are likely due to the rarity of TREM2 variants and small cohort studies with 
not-well characterised cases. 
TREM2 genetic variability in other 
neurodegenerative diseases 
Given the role of TREM2 in microglial function and its involvement in three neurodegenerative 
disorders (AD, FTD, and PLOSL), it has been suggested that TREM2 could be part of a 
functional network involved in various neurodegenerative diseases 91. Consequently, several 
studies have assessed the association of TREM2 variants with risk of developing non-AD 
neurodegenerative disease (appendix). 
In 2013, after the initial findings of the association between TREM2 and AD, an association of 
p.R47H with the risk of Parkinson’s disease (PD) was reported 91. However, in this study, the 
frequency of the variant in healthy controls was below what would be expected given known 
population frequencies. Since the p.R47H variant frequency varies across populations, it is 
imperative that, for this and other rare variants, association tests be performed only in 
sufficiently large and well-matched case-control groups 92. In another study, a significant 
association between p.R47H and PD risk in a discovery cohort of North American patients 
diagnosed with PD and healthy controls was reported, but failed replication in that same study 89 
The association of p.R47H with PD has subsequently failed independent replication in other 
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association studies 33,93. This association was also tested in the Chinese population and no 
significant effect on risk was found, again, with no variant being identified in this population 94–97. 
Other studies have evaluated the impact of TREM2 variants in risk for amyotrophic lateral 
sclerosis 89,98,99, Lewy body dementia 100, posterior cortical atrophy 101, Creutzfeldt-Jakob 
disease 9,29,90, progressive supranuclear palsy 89, ischemic stroke 89, multiple system atrophy 95, 
and essential tremor 102, with conflicting results (appendix). This is, at least in part, because the 
TREM2 variants are rare and only small cohorts of patients have been analysed. Thus, the 
association of TREM2 with the risk for the development of neurodegenerative diseases beyond 
AD has not been robustly replicated so far. Future studies comprising larger cohorts of cases 
and controls will be required to clarify these potential associations. 
Conclusions and future directions 
Although the associations of TREM2 p.R47H and p.R62H variants with risk for AD are well 
established, more studies are required to validate the possible associations of other variants 
within the TREM2 gene, as well as those located within the broader TREM locus. The same is 
true for variants in other neurodegenerative diseases: thus far, studies have yielded 
contradictory results, with the burden of proof not being met. Large-scale studies, preferably 
including populations other than European-Americans, are necessary to more fully understand 
the impact of TREM2 variability on the genetic architecture of AD and other neurodegenerative 
disorders. 
Additionally, further large-scale studies are needed to better understand the impact of TREM2 
variants on clinical presentation, progression, and neuropathology. A limited number of studies 
thus far suggest that AD patients carrying p.R47H present with fairly typical AD symptoms, 
although earlier age of onset and shorter disease duration have been reported 21,29. In addition, 
reduced microglial clustering around plaques was seen at autopsy in p.R47H carriers 48,50. 
However, given the low frequency of TREM2 variants, it is difficult to assemble sufficiently large 
cohorts to establish robust genotype-phenotype correlations. 
Although sTREM2 has been found to be elevated in the CSF of patients with AD, compared with 
controls, it lacks discriminative power for diagnostic procedures 46. However, CSF sTREM2 
appears to exhibit a dynamic response during disease progression 43,44, possibly reflecting 
microglial activity. If validated, sTREM2 could be a potential biomarker for disease progression, 
particularly the transition from preclinical AD to dementia. It is interesting to imagine the use of 
amyloid-β and tau biomarkers for the differential diagnosis of AD, and a panel of other 
biomarkers, including sTREM2, to characterise and stage the disease. 
Additional research is also needed into how TREM2 variants affect risk of AD and cause PLOSL 
and FTD. Evidence thus far suggests that TREM2 variants that result in (partial) loss of protein 
function may impair microglial response to stressors, such as amyloid accumulation in AD 65.  
Evidence points towards TREM2 as a potential therapeutic target. In vivo TREM2 
overexpression ameliorates neuropathological signatures of AD and the memory deficits 
associated with the disease 55. Thus, activation of the TREM2 signaling pathway could offer a 
new therapeutic approach, for example, through the use of small molecules that mimic TREM2 
ligands. It is also important to determine when, during the course of the disease, an intervention 
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increasing TREM2 expression or activation might be most beneficial. The study of familial forms 
of AD can potentially be helpful for this goal, due to the predictability of the age of onset of 
symptoms. It will also be important to systematically characterize the effects of manipulating 
TREM2 levels, both centrally and peripherally. 
In order to fully understand the complex role of TREM2 in the risk of neurodegenerative 
diseases it is essential to systematically integrate the available data. To aggregate the existing 
TREM2 variant data and provide a platform into which new information can be synthesized, we 
have created a TREM2 open access resource on the Alzforum website 
(www.alzforum.org/mutations)—in which information on genetic associations with different 
phenotypes, pathogenicity, neuropathology, biological effects, and research models, are 
available for identified TREM2 variants. This resource currently contains information on 63 
TREM2 variants and will be updated as new findings are published. 
A significant increase in the number of studies related to TREM2 in neurodegenerative diseases 
and the critical integration of these results will allow us to understand its role in 
neurodegenerative disorders, which will facilitate the development of new therapeutic 
interventions. 
Contributors 
All authors contributed equally to the preparation and writing of the manuscript. All authors 
approved the final version. 
Declaration of interests 
All the authors declare no competing interests. 
Acknowledgments 
JB and RG’s work is funded by research fellowships from the Alzheimer's Society. 
Search strategy and selection criteria 
References for this Review were identified by searches of PubMed and BioRxiv databases for 
peer-reviewed, English articles published from Jan 1, 2013, to May 31, 2018. The search terms 
‘TREM2 AND dementia’, ‘TREM2 AND Alzheimer’ and ‘TREM2 AND neurodegeneration’ were 
used. The final reference list was generated on the basis of relevance to the topics covered in 
this Review. 
 
References 
 
1 Jansen I, Savage J, Watanabe K, et al. Genetic meta-analysis identifies 9 novel loci and 
functional pathways for Alzheimers disease risk. bioRxiv. 2018; : 258533. 
12 
2 Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med 
2013; 368: 117–27. 
3 Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of 
Alzheimer’s disease. N Engl J Med 2013; 368: 107–16. 
4 Paloneva J, Manninen T, Christman G, et al. Mutations in two genes encoding different 
subunits of a receptor signaling complex result in an identical disease phenotype. Am J 
Hum Genet 2002; 71: 656–62. 
5 Guerreiro RJ, Lohmann E, Brás JM, et al. Using exome sequencing to reveal mutations in 
TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. 
JAMA Neurol 2013; 70: 78–84. 
6 Forabosco P, Ramasamy A, Trabzuni D, et al. Insights into TREM2 biology by network 
analysis of human brain gene expression data. Neurobiol Aging 2013; 34: 2699–714. 
7 Song W, Hooli B, Mullin K, et al. Alzheimer’s disease-associated TREM2 variants exhibit 
either decreased or increased ligand-dependent activation. Alzheimers Dement 2017; 13: 
381–7. 
8 Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 
implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat Genet 2017; 49: 
1373–84. 
9 Ruiz A, Dols-Icardo O, Bullido MJ, et al. Assessing the role of the TREM2 p.R47H variant 
as a risk factor for Alzheimer’s disease and frontotemporal dementia. Neurobiol Aging 
2014; 35: 444.e1–4. 
10 Cuyvers E, Bettens K, Philtjens S, et al. Investigating the role of rare heterozygous TREM2 
variants in Alzheimer’s disease and frontotemporal dementia. Neurobiol Aging 2014; 35: 
726.e11–9. 
11 Reitz C, Mayeux R, Alzheimer’s Disease Genetics Consortium. TREM2 and 
neurodegenerative disease. N Engl J Med 2013; 369: 1564–5. 
12 Yu J-T, Jiang T, Wang Y-L, et al. Triggering receptor expressed on myeloid cells 2 variant 
is rare in late-onset Alzheimer’s disease in Han Chinese individuals. Neurobiol Aging 2014; 
35: 937.e1–3. 
13 Ma J, Zhou Y, Xu J, et al. Association study of TREM2 polymorphism rs75932628 with late-
onset Alzheimer’s disease in Chinese Han population. Neurol Res 2014; 36: 894–6. 
14 Jiao B, Liu X, Tang B, et al. Investigation of TREM2, PLD3, and UNC5C variants in patients 
with Alzheimer’s disease from mainland China. Neurobiol Aging 2014; 35: 2422.e9–
2422.e11. 
15 Bonham LW, Sirkis DW, Fan J, et al. Identification of a rare coding variant in TREM2 in a 
Chinese individual with Alzheimer’s disease. Neurocase 2017; 23: 65–9. 
16 Miyashita A, Wen Y, Kitamura N, et al. Lack of genetic association between TREM2 and 
late-onset Alzheimer’s disease in a Japanese population. J Alzheimers Dis 2014; 41: 1031–
8. 
13 
17 Chung SJ, Kim M-J, Kim J, et al. Exome array study did not identify novel variants in 
Alzheimer’s disease. Neurobiol Aging 2014; 35: 1958.e13–4. 
18 Mehrjoo Z, Najmabadi A, Abedini SS, et al. Association Study of the TREM2 Gene and 
Identification of a Novel Variant in Exon 2 in Iranian Patients with Late-Onset Alzheimer’s 
Disease. Med Princ Pract 2015; 24: 351–4. 
19 Hooli BV, Parrado AR, Mullin K, et al. The rare TREM2 R47H variant exerts only a modest 
effect on Alzheimer disease risk. Neurology 2014; 83: 1353–8. 
20 Bertram L, Parrado AR, Tanzi RE. TREM2 and neurodegenerative disease. N Engl J Med 
2013; 369: 1565. 
21 Korvatska O, Leverenz JB, Jayadev S, et al. R47H Variant of TREM2 Associated With 
Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological 
Study. JAMA Neurol 2015; 72: 920–7. 
22 Jiang T, Tan L, Chen Q, et al. A rare coding variant in TREM2 increases risk for 
Alzheimer’s disease in Han Chinese. Neurobiol Aging 2016; 42: 217.e1–3. 
23 Schlepckow K, Kleinberger G, Fukumori A, et al. An Alzheimer-associated TREM2 variant 
occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO 
Mol Med 2017; 9: 1356–65. 
24 Thornton P, Sevalle J, Deery MJ, et al. TREM2 shedding by cleavage at the H157‐ S158 
bond is accelerated for the Alzheimer’s disease‐ associated H157Y variant. EMBO Mol 
Med 2017; : e201707673. 
25 Jin SC, Carrasquillo MM, Benitez BA, et al. TREM2 is associated with increased risk for 
Alzheimer’s disease in African Americans. Mol Neurodegener 2015; 10: 19. 
26 Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals 
identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 2013; 45: 1452–8. 
27 Benitez BA, Jin SC, Guerreiro R, et al. Missense variant in TREML2 protects against 
Alzheimer’s disease. Neurobiol Aging 2014; 35: 1510.e19–26. 
28 Carrasquillo MM, Allen M, Burgess JD, et al. A candidate regulatory variant at the TREM 
gene cluster associates with decreased Alzheimer’s disease risk and increased TREML1 
and TREM2 brain gene expression. Alzheimers Dement 2017; 13: 663–73. 
29 Slattery CF, Beck JA, Harper L, et al. R47H TREM2 variant increases risk of typical early-
onset Alzheimer’s disease but not of prion or frontotemporal dementia. Alzheimers Dement 
2014; 10: 602–8.e4. 
30 Rosenthal SL, Bamne MN, Wang X, et al. More evidence for association of a rare TREM2 
mutation (R47H) with Alzheimer’s disease risk. Neurobiol Aging 2015; 36: 2443.e21–6. 
31 Roussos P, Katsel P, Fam P, Tan W, Purohit DP, Haroutunian V. The triggering receptor 
expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, 
neuropathological lesions and increased risk for Alzheimer’s dementia. Alzheimers Dement 
2015; 11: 1163–70. 
14 
32 Luis EO, Ortega-Cubero S, Lamet I, et al. Frontobasal gray matter loss is associated with 
the TREM2 p.R47H variant. Neurobiol Aging 2014; 35: 2681–90. 
33 Lill CM, Rengmark A, Pihlstrøm L, et al. The role of TREM2 R47H as a risk factor for 
Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and 
Parkinson's disease. Alzheimers Dement 2015; 11: 1407–16. 
34 Cruchaga C, Kauwe JSK, Harari O, et al. GWAS of cerebrospinal fluid tau levels identifies 
risk variants for Alzheimer’s disease. Neuron 2013; 78: 256–68. 
35 Piccio L, Deming Y, Del-Águila JL, et al. Cerebrospinal fluid soluble TREM2 is higher in 
Alzheimer disease and associated with mutation status. Acta Neuropathol 2016; 131: 925–
33. 
36 Rajagopalan P, Hibar DP, Thompson PM. TREM2 and neurodegenerative disease. N Engl 
J Med 2013; 369: 1565–7. 
37 Engelman CD, Koscik RL, Jonaitis EM, Hermann BP, La Rue A, Sager MA. Investigation of 
triggering receptor expressed on myeloid cells 2 variant in the Wisconsin Registry for 
Alzheimer’s Prevention. Neurobiol Aging 2014; 35: 1252–4. 
38 Replogle JM, Chan G, White CC, et al. A TREM1 variant alters the accumulation of 
Alzheimer-related amyloid pathology. Ann Neurol 2015; 77: 469–77. 
39 Henjum K, Almdahl IS, Årskog V, et al. Cerebrospinal fluid soluble TREM2 in aging and 
Alzheimer’s disease. Alzheimers Res Ther 2016; 8: 17. 
40 Zhong L, Chen X-F, Wang T, et al. Soluble TREM2 induces inflammatory responses and 
enhances microglial survival. J Exp Med 2017; 214: 597–607. 
41 Kleinberger G, Yamanishi Y, Suárez-Calvet M, et al. TREM2 mutations implicated in 
neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 2014; 6: 
243ra86. 
42 Heslegrave A, Heywood W, Paterson R, et al. Increased cerebrospinal fluid soluble TREM2 
concentration in Alzheimer’s disease. Mol Neurodegener 2016; 11: 3. 
43 Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, et al. sTREM2 cerebrospinal fluid 
levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and 
associate with neuronal injury markers. EMBO Mol Med 2016; 8: 466–76. 
44 Suárez-Calvet M, Araque Caballero MÁ, Kleinberger G, et al. Early changes in CSF 
sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and 
neuronal injury. Sci Transl Med 2016; 8: 369ra178. 
45 Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the Role of TREM2 in 
Alzheimer’s Disease. Neuron 2017; 94: 237–48. 
46 Brosseron F, Traschütz A, Widmann CN, et al. Characterization and clinical use of 
inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease. Alzheimers Res 
Ther 2018; 10: 25. 
47 Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease 
15 
pathogenesis. Nat Rev Neurosci 2016; 17: 201–7. 
48 Yuan P, Condello C, Keene CD, et al. TREM2 Haplodeficiency in Mice and Humans 
Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and 
Severe Axonal Dystrophy. Neuron 2016; 90: 724–39. 
49 Wang Y, Ulland TK, Ulrich JD, et al. TREM2-mediated early microglial response limits 
diffusion and toxicity of amyloid plaques. J Exp Med 2016; 213: 667–75. 
50 Krasemann S, Madore C, Cialic R, et al. The TREM2-APOE Pathway Drives the 
Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. 
Immunity 2017; 47: 566–81.e9. 
51 Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M. Humanized TREM2 mice 
reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med 2018; 
215: 745–60. 
52 Jay TR, Hirsch AM, Broihier ML, et al. Disease Progression-Dependent Effects of TREM2 
Deficiency in a Mouse Model of Alzheimer’s Disease. J Neurosci 2017; 37: 637–47. 
53 Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response 
in an Alzheimer’s disease model. Cell 2015; 160: 1061–71. 
54 Jay TR, Miller CM, Cheng PJ, et al. TREM2 deficiency eliminates TREM2+ inflammatory 
macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med 
2015; 212: 287–95. 
55 Lee CYD, Daggett A, Gu X, et al. Elevated TREM2 Gene Dosage Reprograms Microglia 
Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models. 
Neuron 2018; 97: 1032–48.e5. 
56 Ma L, Allen M, Sakae N, et al. Expression and processing analyses of wild type and 
p.R47H TREM2 variant in Alzheimer’s disease brains. Mol Neurodegener 2016; 11: 72. 
57 Yin J, Liu X, He Q, Zhou L, Yuan Z, Zhao S. Vps35-dependent recycling of Trem2 regulates 
microglial function. Traffic 2016; 17: 1286–96. 
58 Zhao Y, Wu X, Li X, et al. TREM2 Is a Receptor for β-Amyloid that Mediates Microglial 
Function. Neuron 2018; 97: 1023–31.e7. 
59 Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 Binds to Apolipoproteins, 
Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by 
Microglia. Neuron 2016; 91: 328–40. 
60 Bailey CC, DeVaux LB, Farzan M. The Triggering Receptor Expressed on Myeloid Cells 2 
Binds Apolipoprotein E. J Biol Chem 2015; 290: 26033–42. 
61 Atagi Y, Liu C-C, Painter MM, et al. Apolipoprotein E Is a Ligand for Triggering Receptor 
Expressed on Myeloid Cells 2 (TREM2). J Biol Chem 2015; 290: 26043–50. 
62 Zajkowicz A, Gdowicz-Kłosok A, Krześniak M, Janus P, Łasut B, Rusin M. The Alzheimer’s 
disease-associated TREM2 gene is regulated by p53 tumor suppressor protein. Neurosci 
Lett 2018; published online May 26. DOI:10.1016/j.neulet.2018.05.037. 
16 
63 Keren-Shaul H, Spinrad A, Weiner A, et al. A Unique Microglia Type Associated with 
Restricting Development of Alzheimer’s Disease. Cell 2017; 169: 1276–90.e17. 
64 Mazaheri F, Snaidero N, Kleinberger G, et al. TREM2 deficiency impairs chemotaxis and 
microglial responses to neuronal injury. EMBO Rep 2017; 18: 1186–98. 
65 Ulland TK, Song WM, Huang SC-C, et al. TREM2 Maintains Microglial Metabolic Fitness in 
Alzheimer’s Disease. Cell 2017; 170: 649–63.e13. 
66 Leyns CEG, Ulrich JD, Finn MB, et al. TREM2 deficiency attenuates neuroinflammation and 
protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S 
A 2017; 114: 11524–9. 
67 Jiang T, Tan L, Zhu X-C, et al. Silencing of TREM2 exacerbates tau pathology, 
neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice. 
Neurobiol Aging 2015; 36: 3176–86. 
68 Bemiller SM, McCray TJ, Allan K, et al. TREM2 deficiency exacerbates tau pathology 
through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener 
2017; 12: 74. 
69 Pekkarinen P, Hovatta I, Hakola P, et al. Assignment of the locus for PLO-SL, a frontal-lobe 
dementia with bone cysts, to 19q13. Am J Hum Genet 1998; 62: 362–72. 
70 Klünemann HH, Ridha BH, Magy L, et al. The genetic causes of basal ganglia calcification, 
dementia, and bone cysts: DAP12 and TREM2. Neurology 2005; 64: 1502–7. 
71 Chepuru R, Shaik AJ, Tandra SR, Gaddamanugu P, Alladi S, Kaul S. Nasu–Hakola 
disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy): 
First report from India. Neurol India 2018; 66: 538. 
72 Paloneva J, Autti T, Hakola P, Haltia MJ. Polycystic Lipomembranous Osteodysplasia with 
Sclerosing Leukoencephalopathy (PLOSL). In: Adam MP, Ardinger HH, Pagon RA, et al., 
eds. GeneReviews®. Seattle (WA): University of Washington, Seattle, 2002. 
73 Solje E, Hartikainen P, Valori M, et al. C9ORF72 expansion does not affect the phenotype 
in Nasu-Hakola disease with the DAP12 mutation. Neurobiol Aging 2014; 35: 1780.e13–7. 
74 Ghezzi L, Carandini T, Arighi A, et al. Evidence of CNS β-amyloid deposition in Nasu-
Hakola disease due to the TREM2 Q33X mutation. Neurology 2017; : 
10.1212/WNL.0000000000004747. 
75 Montalbetti L, Ratti MT, Greco B, Aprile C, Moglia A, Soragna D. Neuropsychological tests 
and functional nuclear neuroimaging provide evidence of subclinical impairment in Nasu-
Hakola disease heterozygotes. Funct Neurol 2005; 20: 71–5. 
76 Satoh J-I, Kino Y, Yanaizu M, Saito Y. Alzheimer’s disease pathology in Nasu-Hakola 
disease brains. Intractable Rare Dis Res 2018; 7: 32–6. 
77 Kaivola K, Jansson L, Saarentaus E, et al. Heterozygous TYROBP deletion (PLOSLFIN) is 
not a strong risk factor for cognitive impairment. Neurobiol Aging 2018; 64: 159.e1–159.e4. 
78 Darwent L, Carmona S, Lohmann E, et al. Mutations in TYROBP are not a common cause 
17 
of dementia in a Turkish cohort. Neurobiol Aging 2017; 58: 240.e1–240.e3. 
79 Chouery E, Delague V, Bergougnoux A, Koussa S, Serre J-L, Mégarbané A. Mutations in 
TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat 2008; 29. 
http://onlinelibrary.wiley.com/doi/10.1002/humu.20836/full. 
80 Guerreiro RJ, Lohmann E, Brás JM, et al. Using exome sequencing to reveal mutations in 
TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. 
JAMA Neurol 2013; 70: 78–84. 
81 Guerreiro R, Bilgic B, Guven G, et al. A novel compound heterozygous mutation in TREM2 
found in a Turkish frontotemporal dementia-like family. Neurobiol Aging 2013; 34: 2890.e1–
2890.e5. 
82 Ng AS, Tan YJ, Yi Z, et al. Targeted exome sequencing reveals homozygous TREM2 
R47C mutation presenting with behavioral variant frontotemporal dementia without bone 
involvement. Neurobiol Aging 2018; published online April 16. 
DOI:10.1016/j.neurobiolaging.2018.04.003. 
83 Le Ber I, De Septenville A, Guerreiro R, et al. Homozygous TREM2 mutation in a family 
with atypical frontotemporal dementia. Neurobiol Aging 2014; 35: 2419.e23–2419.e25. 
84 Redaelli V, Salsano E, Colleoni L, et al. Frontotemporal Dementia and Chorea Associated 
with a Compound Heterozygous TREM2 Mutation. J Alzheimers Dis 2018; 63: 195–201. 
85 Chee KY, Gaillard F, Velakoulis D, Ang CL, Chin LK, Ariffin R. A case of TREM2 mutation 
presenting with features of progressive non-fluent aphasia and without bone involvement. 
Aust N Z J Psychiatry 2017; 51: 1157–8. 
86 Giraldo M, Lopera F, Siniard AL, et al. Variants in triggering receptor expressed on myeloid 
cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and 
Alzheimer’s disease. Neurobiol Aging 2013; 34: 2077.e11–8. 
87 Thelen M, Razquin C, Hernández I, et al. Investigation of the role of rare TREM2 variants in 
frontotemporal dementia subtypes. Neurobiol Aging 2014; 35: 2657.e13–2657.e19. 
88 Borroni B, Ferrari F, Galimberti D, et al. Heterozygous TREM2 mutations in frontotemporal 
dementia. Neurobiol Aging 2014; 35: 934.e7–10. 
89 Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neurodegeneration: evidence for 
association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease. 
Mol Neurodegener 2013; 8: 19. 
90 Lattante S, Le Ber I, Camuzat A, et al. TREM2 mutations are rare in a French cohort of 
patients with frontotemporal dementia. Neurobiol Aging 2013; 34: 2443.e1–2. 
91 Benitez BA, Cruchaga C, United States–Spain Parkinson’s Disease Research Group. 
TREM2 and neurodegenerative disease. N Engl J Med 2013; 369: 1567–8. 
92 Guerreiro R, Hardy J. TREM2 and neurodegenerative disease. N Engl J Med 2013; 369: 
1569–70. 
93 Mengel D, Thelen M, Balzer-Geldsetzer M, et al. TREM2 rare variant p.R47H is not 
18 
associated with Parkinson’s disease. Parkinsonism Relat Disord 2016; 23: 109–11. 
94 Feng S-J, Nie K, Gan R, et al. Triggering receptor expressed on myeloid cells 2 variants 
are rare in Parkinson’s disease in a Han Chinese cohort. Neurobiol Aging 2014; 35: 
1780.e11–2. 
95 Chen Y, Chen X, Guo X, et al. Assessment of TREM2 rs75932628 association with 
Parkinson’s disease and multiple system atrophy in a Chinese population. Neurol Sci 2015; 
36: 1903–6. 
96 Tan T, Song Z, Yuan L, et al. Genetic analysis of TREM2 variants in Chinese Han patients 
with sporadic Parkinson’s disease. Neurosci Lett 2016; 612: 189–92. 
97 Li Z, Zhong L, Gu L, et al. Association study of TREM2 polymorphism rs75932628 with 
leucoaraiosis or Parkinson’s disease in the Han Chinese population. BMJ Open 2016; 6: 
e009499. 
98 Cady J, Koval ED, Benitez BA, et al. TREM2 variant p.R47H as a risk factor for sporadic 
amyotrophic lateral sclerosis. JAMA Neurol 2014; 71: 449–53. 
99 Chen X, Chen Y, Wei Q, et al. Assessment of TREM2 rs75932628 association with 
amyotrophic lateral sclerosis in a Chinese population. J Neurol Sci 2015; 355: 193–5. 
100 Walton RL, Soto-Ortolaza AI, Murray ME, et al. TREM2 p.R47H substitution is not 
associated with dementia with Lewy bodies. Neurol Genet 2016; 2: e85. 
101 Carrasquillo MM, Barber I, Lincoln SJ, et al. Evaluating pathogenic dementia variants in 
posterior cortical atrophy. Neurobiol Aging 2016; 37: 38–44. 
102 Ortega-Cubero S, Lorenzo-Betancor O, Lorenzo E, et al. TREM2 R47H variant and risk of 
essential tremor: a cross-sectional international multicenter study. Parkinsonism Relat 
Disord 2015; 21: 306–9. 
103 Jay TR, von Saucken VE, Landreth GE. TREM2 in Neurodegenerative Diseases. Mol 
Neurodegener 2017; 12: 56. 
104 Ito H, Hamerman JA. TREM-2, triggering receptor expressed on myeloid cell-2, negatively 
regulates TLR responses in dendritic cells. Eur J Immunol 2012; 42: 176–85. 
105 Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J. Sequential 
proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) 
protein by ectodomain shedding and γ-secretase-dependent intramembranous cleavage. J 
Biol Chem 2013; 288: 33027–36. 
106 Feuerbach D, Schindler P, Barske C, et al. ADAM17 is the main sheddase for the 
generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain 
and cleaves TREM2 after Histidine 157. Neurosci Lett 2017; 660: 109–14. 
 
Panel: TREM2 and the TREM locus  
19 
TREM locus 
TREM2 is located within a gene cluster on chromosome 6p21.1, near TREM1, TREML1, 
TREML2, TREML3P, TREML4, and NCR2. The genes in this cluster have significant homology 
and are mostly involved in immunological functions. 
TREM2 expression 
The triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane receptor of 
the immunoglobulin superfamily expressed in cells of the myeloid lineage, including microglia 
and osteoclasts, that participates in modulation of the immune system 47,103. In the CNS the 
signal intensity levels of TREM2 transcripts are strongest in the basal ganglia, corpus callosum, 
medulla oblongata, and spinal cord 4. 
TREM2 ligands and signaling cascade 
TREM2 binds anionic ligands including bacterial lipopolysaccharides, DNA and phospholipids 53. 
Ligand binding to TREM2 initiates a signaling cascade in which the TREM2-associated 
intracellular adaptor TYROPB (or DAP12) is phosphorylated. Phosphorylated TYROBP recruits 
the protein tyrosine kinase SYK, which in turn induces PI3K activation, followed by AKT 
activation, MAPK activation, Ca2+ mobilization, and other downstream effects 47. Activation of 
these pathways modulates cell proliferation and differentiation, survival, phagocytosis, 
chemotaxis, and inflammation 47103. In certain contexts, TREM2 signaling can also be inhibitory, 
with a negative regulation of TLR-response found to be mediated by TREM2 in dendritic cells 
104.  
TREM2 cleavage and soluble TREM2  
TREM2, a type I membrane glycoprotein, can be subjected to sequential proteolytic processing. 
Cleavage by alpha secretases (ADAM10 and ADAM17) occurring after the H157 residue of the 
protein, results in ectodomain shedding, releasing soluble TREM2 into the extracellular space 
105. Gamma-secretase then cleaves teh remaining C-terminal portion 23,24,106. 
 
 
 
 
 
 
 
 
 
